FDA (CDER)
GUIDANCE FINAL
Pulmonary Tuberculosis: Developing Drugs for Treatment
Published: 5/8/2026Detected: 5/8/2026
Summary preview
Developing Drugs for the treatment of pulmonary tuberculosis outlines FDA’s expectations for how sponsors should design and support drug development, including clinical evidence generation, benefit-risk assessment, and…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
respiratory
clinical
safety
labeling
quality
#pulmonary tuberculosis
#drug development
#clinical endpoints
#safety monitoring
#benefit-risk
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026